Abstract
All cancers arise as a result of the acquisition of a series of fixed DNA
sequence abnormalities, mutations, many of which ultimately confer a growth
advantage upon the cells in which they have occurred. Protein kinases have
been implicated in many aspects of tumorigenesis and protein kinase inhibitors
(PKIs) have there of arisen as a major therapeutic class of compounds for the
treatment of cancer. The plethora of new potential therapeutic drugs have made
selection and validation of novel molecular targets of paramount importance
First in place, BioSeeker has surveyed protein kinase inhibitors in oncology
and identified 110 drug targets, belonging to 210 protein kinase inhibitor
drugs. This report, The Drug Target Atlas of Protein Kinase Inhibitors in
Oncology, is an open landscape of resources to build, fuel, and drive your
scientific competitive vehicle for the advancement of new protein kinase
inhibitor drugs in oncology
In the report, BioSeeker reports on 139 unique drug target combinations, each
comprised of a different collection or mix of individually defined targets,
for 210 PKI drugs designed for the treatment of more than 50 different cancer
indications. The highest degree of distinctiveness among PKIs is achieved by
sorting each of them according to targeted cancer indication, drug target mix,
and drug compound type. At the same time we are also identifying peer groups
of drugs, that is, drugs we consider suitable for head-to-head comparison
during drug development
To fuel the scientific and competitive thinking, BioSeeker opens the gate into
the presence and relevance of protein-protein interactions between identified
PKI drug targets. No less than 519 protein-protein interactions were
recognized among 98 of the 110 included PKI drug targets
The report by the numbers:
- 300+ pages, with almost a hundred different tables. Includes close to
1,000 active links to related resources on the Internet
- 210 Protein kinase inhibitor drugs, under development by 107
investigators, are included, covering more than 600 developmental projects in
cancer
- 110 Unique, in-depth, drug target profiles, highlighting twelve themes
about the drug target, i.e. protein-protein interaction with other PKI drug
targets, linked cancer indications, presence in the Cancer Genome Project etc
- 139 Unique drug target combinations of PKI drugs
- 519 protein-protein interactions among PKI drug targets
- 20 Major signaling pathways covered
View Cart
